What development phase is IOFETAMINE in?

IOFETAMINE is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

IOFETAMINE

FDA-approved approved Small molecule Quality 6/100

Iofetamine is a marketed drug with an unclear mechanism of action, primarily used for an unspecified indication. The drug holds a key composition patent expiring in 2028, which provides a period of market exclusivity. The primary risk is the lack of detailed clinical trial results and revenue data, which may limit investor confidence and market adoption.

At a glance

Generic name	IOFETAMINE
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved
First approval	1987

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

IOFETAMINE CI brief — competitive landscape report
IOFETAMINE updates RSS · CI watch RSS